High-dose_medroxyprogesterone_acetate_versus_estramustine_in_therapy-resistant_prostatic_cancer:_a_randomised_study._A_series_of_105_patients_with_metastatic_prostatic_cancer,_having_progressed_on_first-line_hormonal_treatment,_were_randomised_to_high-dose_medroxyprogesterone_acetate_(MPA)_1000_mg_i.m._daily_for_15_days,_followed_by_1000_mg_weekly_(53_patients),_or_to_estramustine_280_mg_per_os_twice_daily_(52_patients)._The_treatment_was_discontinued_because_of_side_effects_in_3_of_51_evaluable_MPA-treated_patients_and_in_8_of_51_evaluable_estramustine-treated_patients._Progression-free_survival_was_short_in_both_groups_and_no_statistically_significant_difference_between_them_was_observed._After_1_year,_70%_of_the_patients_had_died_and_there_was_no_statistically_significant_difference_between_the_2_treatments_in_the_cumulative_observed_survival_rates._According_to_modified_SPCG_criteria,_remissions_lasting_from_12_to_56_weeks_were_noted_in_13_MPA-treated_patients_and_in_4_estramustine-treated_patients._This_difference_was_statistically_significant._After_cross-over,_6_of_33_patients_in_the_MPA_group_had_a_remission_compared_with_1_of_24_in_the_estramustine_group._It_was_concluded_that_the_response_rate,_considering_both_subjective_and_objective_response_criteria,_was_better_with_MPA_and_the_side_effects_were_fewer.